AstraZeneca: Observational study closed enrollment, 367 enrolled (Atypical Hemolytic Uremic Syndrome(aHUS))
AstraZeneca: Observational study closed enrollment, 367 enrolled (Atypical Hemolytic Uremic Syndrome(aHUS)). Its enrollment of 367 is above the median of 80 (85th percentile). Dated 10 days ago, it is in the active follow-up window. Score 85/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 367 · 85th percentile of 8,879 ClinicalTrialStartPulse records · 4.6x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | AstraZeneca |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients |
| NCT ID | NCT06099236 |
| Phase | Observational |
| Status | active not recruiting |
| Conditions | Atypical Hemolytic Uremic Syndrome(aHUS) |
| Target enrollment | 367 |
| Site countries | China |
| Posted | 2023-10-25 |
| Planned start | 2024-01-15 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-26 |
| Last update posted | 2026-10-26 |
| enrollment percentile | 85th of 8,879 (median 80, 4.6x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch AstraZeneca
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock AstraZeneca + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-26
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: AstraZeneca and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- AstraZeneca's enrollment: 85th percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
85 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 367 participants planned.
What is the ClinicalTrialStartPulse record for AstraZeneca?
AstraZeneca's Observational study (NCT06099236) in Atypical Hemolytic Uremic Syndrome(aHUS), first posted 2023-10-25: enrollment closed (active, not recruiting) (2026-10-26), in an update posted 2026-10-26.
How does AstraZeneca compare to other ClinicalTrialStartPulse records?
Its enrollment of 367 sits in the upper half (85th percentile) of 8,879 records; the median is 80. It is fresh: dated 10 days ago, inside the window where early outreach matters most. Its Score of 85/100 puts it among the stronger signals in this feed.
AstraZeneca vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| AstraZeneca | NONUS | 367 | 85th | 2026-10-26 |
| Janssen-Cilag International NV | NONUS | 135 | 68th | 2026-11-03 |
| Janssen Pharmaceutica N.V., Belgium | NONUS | 1,314 | 95th | 2026-11-03 |
| Hoffmann-La Roche | NONUS | 1,800 | 96th | 2026-10-30 |
Related records
ClinicalTrialStartPulse: Observational ClinicalTrialStartPulse: Outside the US only
How to monitor AstraZeneca and peer observational records
Get new ClinicalTrialStartPulse records like AstraZeneca by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.